on Thursday, September 26, 2013
On the occasion of Childhood Cancer Awareness Month, pediatric oncologist Paul A. Meyers talks about the evolution of pediatric cancer research and treatment at Memorial Sloan Kettering.
Fifty years ago, the most common type of childhood cancer, acute lymphoblastic leukemia (ALL), was almost uniformly fatal. Today, cure rates for ALL can reach as high as 90 percent. Much of this success is due to the early and groundbreaking work of Memorial Sloan Kettering physician-scientists.
“The introduction of chemotherapy in leukemia was a huge undertaking,” says pediatric oncologist Paul A. Meyers. “It happened pretty much simultaneously at what is now the Dana-Farber Cancer Institute [formerly the Children’s Hospital of Boston], and here at Memorial Sloan Kettering. The effort was led by people like [medical oncologists] Joseph Burchenal and David Karnofsky, and [pediatric oncologist] Lois Murphy. Dr. Murphy was one of the first pediatricians to work in Memorial Hospital and collaborating with Drs. Burchenal and Karnofsky, she was among the first to treat children with chemotherapy.”
A number of drugs that are now standard agents for the treatment of leukemia were first introduced at Memorial Sloan Kettering, including l-asparaginase and the anthracyclines doxorubicin and daunorubicin. “And some of the very first clinical trials that used combination chemotherapy were also done here,” says Dr. Meyers. “That concept — of putting drugs together to treat cancer — also had its genesis here.”
And within the last decade, a new drug for the treatment of childhood leukemia, clofarabine, was approved by the US Food and Drug Administration on the strength of work done by Dr. Meyers and his colleagues.
“There came a point in the history of developing treatments for childhood leukemia when people realized they needed to work collaboratively,” Dr. Meyers continues. “And so the Acute Leukemia Group A (ALGA) was founded.” Lois Murphy was the first chair of the ALGA, which eventually led to what is today the Children’s Oncology Group.
“So even the concept of multi-institutional collaborations was born on this very block,” Dr. Meyers says.Back to top
“When [Department of Pediatrics Chair] Richard O’Reilly founded the Pediatric Bone Marrow Transplant Service more than 30 years ago, it was one of the original transplant centers in the United States,” notes Dr. Meyers. “And since that time the service has been a transplantation pioneer.”
Important advances have included the first successful transplants using marrow from an unrelated donor; the introduction of T cell depletion as a way to prevent graft-versus-host disease, which is the most frequent serious complication following transplantation; the introduction of hyperfractionated total body irradiation, a method of delivering radiation therapy before a transplant to increase the antileukemia and antitumor effects of radiotherapy while decreasing the short- and long-term side effects of radiation; and the use of immune cells derived from blood to treat viral infections or relapse of disease after a transplant.Back to top
Dr. Meyers, who directs clinical research aimed at developing and evaluating new therapies for sarcomas, cancers that arise in the bone, muscle, or connective tissue, also points to the fact that the first limb-sparing surgery done for a sarcoma of the extremity was performed at Memorial Sloan Kettering.
“And the idea of giving chemotherapy before surgery for the treatment of pediatric solid tumors is yet another advance that had its genesis here,” Dr. Meyers says.Back to top
“There are lots of exciting things happening right now,” Dr. Meyers says. “In particular, cell-based immune therapies hold enormous promise.”
In addition to using immune cells to attack viral infections that can arise in patients going through transplant, Memorial Sloan Kettering physician-scientists are now using them to attack tumors that arise in response to certain viruses, like Epstein-Barr. “We’re also using adoptive immunotherapy as a strategy for targeting cancer cells that produce certain proteins abnormally,” says Dr. Meyers.
One of these is WT-1, a protein that is overexpressed in a range of leukemias and other cancers. “We are growing T cells directed against WT-1 in the laboratory to treat patients for whom standard therapy has failed to control their disease,” he explains.
“We also have an active program using chimeric antigen receptors, which allow T cells to target antigens on the surface of a tumor cell. We’re now doing this in pediatric leukemia and have had dramatic successes,” says Dr. Meyers. “Kids who have failed every known therapy get treated with these genetically modified T cells and go into remission. It’s an amazing accomplishment.”
Standard treatment for a neuroblastoma (a tumor that arises from primitive cells of the sympathetic nervous system) has been intensive chemotherapy, often combined with stem cell transplantation. But for more than 20 years Memorial Sloan Kettering investigators have used an antibody called 3F8 in combination with surgery and chemotherapy to treat neuroblastoma, and have significantly improved cure rates for children with high-risk disease.
“We’re now about to embark on a phase III clinical trial to treat osteosarcoma with 3F8, because osteosarcoma expresses the same antigen that is expressed in neuroblastoma,” Dr. Meyers reports. Memorial Sloan Kettering physician-scientists are also studying the use of newer antibody-based therapies to fight neuroblastoma and other cancers, including a rare tumor that arises in the abdomen called desmoplastic small round-cell tumor.
In addition, Memorial Sloan Kettering has a new gene therapy for the inherited blood disorder, thalassemia. “We believe it may have promise to cure — not simply to treat — this devastating disease,” Dr. Meyers says.
“I think most of us feel that chemotherapy has probably reached the limits of its ability to impact childhood cancers and that future advances are going to come from immune- and gene-based therapies,” he concludes.Back to top
Returning Children to Physical, Emotional, and Psychosocial Health
“When you’re treating a child you have to consider the consequences of that treatment for decades to come,” Dr. Meyers explains. “If we succeed in curing the cancer, you’re looking at 50, 60, 70 more years of life.” Because children have not yet physically, sexually, or intellectually matured, anything physicians do that may interfere with these processes can have long-term effects.
“We also have to think about the emergence of second therapy-related cancers,” Dr. Meyers says. “So with every treatment decision we make we want to be certain we’re giving treatments with the greatest possible chance for a cure but that also minimize both the short- and long-term effects of the therapy.”
Dr. Meyers and his colleagues work diligently with families, friends, teachers, and community-support networks to sustain children emotionally and socially through treatment. “We want to ensure that every child comes out of cancer treatment the same child that went in,” he says. “Of course we want to return them to physical health, but also to emotional and psychosocial health.”Back to top